Fangfang Dou
- Topics
- Atherosclerosis and Cardiovascular Diseases (5 papers)Peroxisome Proliferator-Activated Receptors (4 papers)Cancer, Lipids, and Metabolism (3 papers)
- Partner nations
- ChinaUnited StatesCanada
In The Last Decade
Fangfang Dou
25 papers receiving 617 citations
Peers
Comparison fields: 5 of 79
- Molecular Biology 245
- Immunology 129
- Plant Science 109
- Neurology 92
- Physiology 84
Countries citing papers authored by Fangfang Dou
This map shows the geographic impact of Fangfang Dou's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Fangfang Dou with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Fangfang Dou more than expected).
Fields of papers citing papers by Fangfang Dou
This network shows the impact of papers produced by Fangfang Dou. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Fangfang Dou. The network helps show where Fangfang Dou may publish in the future.
Co-authorship network of co-authors of Fangfang Dou
This figure shows the co-authorship network connecting the top 25 collaborators of Fangfang Dou. A scholar is included among the top collaborators of Fangfang Dou based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Fangfang Dou. Fangfang Dou is excluded from the visualization to improve readability, since they are connected to all nodes in the network.
All Works
| # | Work | Indexed citations |
|---|---|---|
| 1 | 1 | |
| 2 | 2 | |
| 3 | 4 | |
| 4 | 19 | |
| 5 | 10 | |
| 6 | 51 | |
| 7 | 3 | |
| 8 | 37 | |
| 9 | 23 | |
| 10 | 5 | |
| 11 | Efficacy of Shoushen granule on adenosine triphosphate binding cassette transporter A1, proprotein convertase subtilisin/kexin type 9 and toll-like receptor 4/nuclear factor kappa-B signaling pathway in ApoE-knockout mice. | 3 |
| 12 | 92 | |
| 13 | Anti-atherosclerotic effects of LXRα agonist through induced conversion of M1 macrophage to M2. | 12 |
| 14 | 11 | |
| 15 | 26 | |
| 16 | 25 | |
| 17 | 91 | |
| 18 | 16 | |
| 19 | 14 | |
| 20 | 15 |
About Fangfang Dou
Fangfang Dou is a scholar working on Aging, Geriatrics and Gerontology and Biological Psychiatry, having authored 25 papers that have together received 622 indexed citations. Recurring topics across this work include Atherosclerosis and Cardiovascular Diseases (5 papers), Peroxisome Proliferator-Activated Receptors (4 papers) and Cancer, Lipids, and Metabolism (3 papers). The work is most often cited by research in Neurology (92 citations), Biological Psychiatry (19 citations) and Immunology (129 citations). Fangfang Dou has collaborated with scholars based in China, United States and Canada. Frequent co-authors include Zhihua Yu, Chuan Chen, Jia Lu, Fengwang Ma, Xiaoqing Gong, Qingling Jia, Hui Cao, Dingzhu Shen, Yi Song and Chenfei Wang. Their work appears in journals such as SHILAP Revista de lepidopterología, Molecules and Gene.
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.